We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+4.24%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$5.08B
AUM Growth
-$217M
(-4.1%)
Cap. Flow
+$248M
Cap. Flow
% of AUM
4.88%
Top 10 Holdings %
Top 10 Hldgs %
55.13%
Holding
68
New
14
Increased
10
Reduced
3
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMGN
Immunogen Inc
IMGN
|
+$183M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
+$92M |
| 3 |
Evolent Health
EVH
|
+$76.1M |
| 4 |
Apogee Therapeutics
APGE
|
+$43.6M |
| 5 |
ARS Pharmaceuticals
SPRY
|
+$42.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
+$365M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$47.3M |
| 3 |
Cytek Biosciences
CTKB
|
+$44M |
| 4 |
Design Therapeutics
DSGN
|
+$18.7M |
| 5 |
CVAC
CureVac
CVAC
|
+$14.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
GH Research
GHRS
$1.93B
| $56.2M | 1.11% |
5,587,333
| – | – |
|
|
ALPN
27
DELISTED
Alpine Immune Sciences Inc
ALPN
| $53.7M | 1.06% |
4,691,178
| – | – |
|
28
4D Molecular Therapeutics
FDMT
$532M
| $53M | 1.04% |
4,163,211
+1,093,680
| +36% | +$18.3M |
|
29
Fulcrum Therapeutics
FULC
$273M
| $51.5M | 1.01% |
11,609,704
| – | – |
|
|
ITOS
30
DELISTED
iTeos Therapeutics
ITOS
| $48.4M | 0.95% |
4,417,259
| – | – |
|
31
Vor Biopharma
VOR
$1.15B
| $48.2M | 0.95% |
1,137,444
| – | – |
|
|
ICVX
32
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $46.2M | 0.91% |
5,963,565
| – | – |
|
33
Acrivon Therapeutics
ACRV
$64.2M
| $46M | 0.91% |
4,810,508
| – | – |
|
|
34
Apogee Therapeutics
APGE
$10.1B
| $42.1M | 0.83% |
+1,977,901
| New | +$43.6M |
|
35
PepGen
PEPG
$122M
| $41.3M | 0.81% |
8,131,952
| – | – |
|
|
RNAM
36
DELISTED
Avidity Biosciences
RNAM
| $40.9M | 0.81% |
6,416,998
| – | – |
|
|
37
Cytek Biosciences
CTKB
$545M
| $37.6M | 0.74% |
6,809,404
-5,488,317
| -45% | -$44M |
|
|
SLNO
38
DELISTED
Soleno Therapeutics
SLNO
| $36.6M | 0.72% |
+1,239,000
| New | +$7.5M |
|
|
39
ARS Pharmaceuticals
SPRY
$509M
| $35.8M | 0.7% |
9,459,678
+6,450,000
| +214% | +$42.3M |
|
|
CLYM
40
Climb Bio
CLYM
$681M
| $34.6M | 0.68% |
13,150,849
| – | – |
|
41
Viridian Therapeutics
VRDN
$2.09B
| $30.8M | 0.61% |
2,007,946
| – | – |
|
42
Pliant Therapeutics
PLRX
$64.4M
| $30.6M | 0.6% |
1,762,000
| – | – |
|
43
Mineralys Therapeutics
MLYS
$2.25B
| $30.2M | 0.6% |
3,178,476
| – | – |
|
44
Aclaris Therapeutics
ACRS
$726M
| $30.1M | 0.59% |
4,398,453
| – | – |
|
45
Madrigal Pharmaceuticals
MDGL
$10.8B
| $29.9M | 0.59% |
+204,500
| New | +$38.5M |
|
46
Enliven Therapeutics
ELVN
$3.92B
| $29M | 0.57% |
2,122,465
| – | – |
|
47
EyePoint Inc
EYPT
$1.03B
| $26.9M | 0.53% |
3,370,506
| – | – |
|
48
UroGen Pharma
URGN
$1.86B
| $20.8M | 0.41% |
+1,483,697
| New | +$23.8M |
|
49
Tenaya Therapeutics
TNYA
$161M
| $17.1M | 0.34% |
6,718,483
+651,000
| +11% | +$2.73M |
|
|
BCYC
50
Bicycle Therapeutics
BCYC
$269M
| $16.1M | 0.32% |
+800,000
| New | +$18.3M |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q3 2023 Portfolio in Review
As of Q3 2023, RA Capital Management held 68 positions worth $5.08B, down 4.1% from $5.3B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
RA Capital Management deployed $248M of net new capital in Q3 2023, opening 14 new positions and adding to 10 existing holdings. Its largest new stake was Cymabay Therapeutics: 6,940,000 shares worth $103M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.
On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $47.3M trimmed.
- RA Capital Management's largest Q3 2023 buy was Cymabay Therapeutics: 6,940,000 shares worth $103M.
- RA Capital Management added most to Immunogen Inc in Q3 2023, an estimated $183M increase.
- RA Capital Management's biggest Q3 2023 reduction was Ascendis Pharma A/S, cutting an estimated $47.3M.
- RA Capital Management fully exited DICE Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $365M.
- RA Capital Management's ten largest holdings make up 55% of its $5.08B portfolio in Q3 2023.
- RA Capital Management opened 14 new positions and closed 2 in Q3 2023.
- RA Capital Management's portfolio value fell 4.1% quarter-over-quarter to $5.08B.
Based on RA Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.